IPO Year: 2024
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | $13.00 | Buy | UBS |
| 10/9/2024 | $16.00 | Buy | Rodman & Renshaw |
| 7/3/2024 | $8.00 | Neutral | H.C. Wainwright |
| 3/4/2024 | $40.00 | Overweight | Morgan Stanley |
| 3/4/2024 | $39.00 | Overweight | JP Morgan |
| 3/4/2024 | $44.00 | Overweight | Wells Fargo |
| 3/4/2024 | $48.00 | Outperform | Leerink Partners |
Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference call on April 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis EMERYVILLE, Calif., April 11, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
UBS initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $13.00
Rodman & Renshaw initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $16.00
H.C. Wainwright initiated coverage of Kyverna Therapeutics with a rating of Neutral and set a new price target of $8.00
Morgan Stanley initiated coverage of Kyverna Therapeutics with a rating of Overweight and set a new price target of $40.00
JP Morgan initiated coverage of Kyverna Therapeutics with a rating of Overweight and set a new price target of $39.00
Wells Fargo initiated coverage of Kyverna Therapeutics with a rating of Overweight and set a new price target of $44.00
Leerink Partners initiated coverage of Kyverna Therapeutics with a rating of Outperform and set a new price target of $48.00
Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026 Advancing into registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) following successful end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA); Phase 2 MG data anticipated in 2H 2025 Company to host KOL event in Q3 2025, spotlighting its accelerating neuroinflammation franchise Strong financial position; cash runway into 2027 supports first BLA filing, MG Phase 3 trial and pre-launch activities EMERYVILLE, Calif., May 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc.
Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 trial design for ongoing KYSA-8 trial in stiff person syndrome; 70% of study enrolled with topline data expected in 1H 2026; Biologics License Application (BLA) filing targeted for 2026 Clinical data in myasthenia gravis and lupus nephritis expected in 2H 2025 Strong balance sheet extends cash runway into 2027 through key clinical and regulatory catalysts EMERYVILLE, Calif., March 27, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company fo
EMERYVILLE, Calif., March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET. A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on th
Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of growth EMERYVILLE, Calif., Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Development Officer, where he will lead the Company's research, clinical development, and medical affairs functions. Dr. Gehchan brings 20 years of U.S. and international experience across multiple
Extending Company's leadership position in autoimmune CAR T with prioritized indication strategy; pivoting to late-stage development and commercialization First-to-market opportunity with KYV-101 in stiff person syndrome; 40% enrolled in pivotal Phase 2 trial with first BLA filing targeted for 2026; fast-follow indications in myasthenia gravis and lupus nephritis Efficiently expanding into broader autoimmune indications and increasing patient reach with KYV-102 using whole blood rapid manufacturing Cash runway into 2027 to deliver key milestones EMERYVILLE, Calif., Jan. 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company fo
SANTA CRUZ, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today the appointment of Abbas Kazimi and Mert Aktar to its Board of Directors. "We are honored to welcome Abbas and Mert to our Board of Directors," said Cameron Pye, Ph.D., CEO and Co-Founder of Unnatural Products. "Abbas has an exceptional history of advancing groundbreaking therapies and forging impactful partnerships, and Mert's vast experience in leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms will be instrumental as we a
EMERYVILLE, Calif., Jan. 6, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced that the Company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. Warner Biddle, Chief Executive Officer of Kyverna, will present its 2025 strategic priorities and key milestones during a presentation on Monday, January 13, 2025, at 5:15 p.m. PST. A live audio webcast of the presentation may be accessed via the Investors section
Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations. "I'm pleased to welcome three industry leaders to our Kyverna team," sai
Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis (LN) Treated With KYV-101 Target Dose KYV-101 Treatment Continues to Demonstrate Robust Safety and Tolerability With No High-Grade CRS or ICANS Observed EMERYVILLE, Calif., Nov. 14, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announces today that it will present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase 1/2 studies and named patient treatments. Kyverna, alongside leading academi
Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development Program: Presented Clinical Data Highlighting Potential for KYV-101 in SPS, MG and MS at ECTRIMS and Plan to Share Updated Clinical Data in LN at Company Symposium at ACR Convergence 2024 Strong Financial Position; Ended the Quarter With $321.6 Million in Cash, Cash Equivalents and Marketable Securities EMERYVILLE, Calif., Nov. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune
10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
EFFECT - Kyverna Therapeutics, Inc. (0001994702) (Filer)
424B5 - Kyverna Therapeutics, Inc. (0001994702) (Filer)
DEFA14A - Kyverna Therapeutics, Inc. (0001994702) (Filer)
DEF 14A - Kyverna Therapeutics, Inc. (0001994702) (Filer)
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
S-8 - Kyverna Therapeutics, Inc. (0001994702) (Filer)
S-3 - Kyverna Therapeutics, Inc. (0001994702) (Filer)
10-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of growth EMERYVILLE, Calif., Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Development Officer, where he will lead the Company's research, clinical development, and medical affairs functions. Dr. Gehchan brings 20 years of U.S. and international experience across multiple
SANTA CRUZ, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today the appointment of Abbas Kazimi and Mert Aktar to its Board of Directors. "We are honored to welcome Abbas and Mert to our Board of Directors," said Cameron Pye, Ph.D., CEO and Co-Founder of Unnatural Products. "Abbas has an exceptional history of advancing groundbreaking therapies and forging impactful partnerships, and Mert's vast experience in leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms will be instrumental as we a
Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations. "I'm pleased to welcome three industry leaders to our Kyverna team," sai
Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms, including cell therapy EMERYVILLE, Calif., Oct. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of biotechnology executive and cell therapy veteran Mert Aktar as an independent director to its Board of Directors. Mr. Aktar has over two decades of biopharmaceutical experience, melding more tha
The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants The clinical study will be supported by cutting edge correlative studies funded through a parallel research collaboration between Kyverna and Stanford University The agreements further expand the scale of ongoing clinical studies assessing the potential therapeutic effects of KYV-101 in multiple diseases and locations around the world EMERYVILLE, Calif., March 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapie